ArticleBMC immunology2026

The efficacy analysis of immunotherapy rechallenge after progression from first-line chemo-immunotherapy in advanced non-small cell lung cancer.

Wenhao Shi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.